体外研究 (In Vitro) |
DIM-3,5-Cl2 (2.5-15 μM) 可强效抑制人源 MDA-MB-231、MDA-MB-468 以及小鼠 4T1 三阴性乳腺癌 (TNBC) 细胞的活力。 DIM-3,5-Cl2 (7-15 μM; 24 h for MDA-MB-231, MDA-MB-468; 10-15 μM; 24 h for 4T1) 可通过诱导剪切型 PARP 和剪切型 caspase-3 的表达、下调促存活蛋白 BCL-2、全长 PARP 及全长 caspase-3,诱导人源 MDA-MB-231、MDA-MB-468 和鼠源 4T1 三阴性乳腺癌 (TNBC) 细胞发生凋亡。 DIM-3,5-Cl2 (对 MDA-MB-231、MDA-MB-468 细胞为 7-15 μM;24 h;对 4T1 细胞为 10-15 μM;24 h) 可通过下调 GPX4 和 SLC7A11 的表达、在中低浓度 (7, 10 μM) 时诱导 CD71 表达而在高浓度 (12, 15 μM) 时下调 CD71 表达,调控人源 MDA-MB-231、MDA-MB-468 和小鼠源 4T1 三阴性乳腺癌 (TNBC) 细胞中与铁死亡相关的蛋白。 DIM-3,5-Cl2 (10-12 μM; 24 h) 可在人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中下调促癌蛋白 EGFR、β1 整合素和 c-Myc。 DIM-3,5-Cl2 (12 μM; 16 h) 可在人源 MDA-MB-231、MDA-MB-468 以及小鼠 4T1 三阴性乳腺癌 (TNBC) 细胞中强效诱导 ROS 生成。 DIM-3,5-Cl2 (12 μM; 16 h) 可在人源 MDA-MB-231、MDA-MB-468 以及小鼠 4T1 三阴性乳腺癌 (TNBC) 细胞中强效诱导脂质过氧化。 DIM-3,5-Cl2 (12 μM; 24 h) 在人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中介导的 CD71、GPX4 和 SLC7A11 表达下调可被铁死亡抑制剂 Ferrostatin-1 (MS-K98895) 逆转,证实 DIM-3,5-Cl2 通过铁死亡途径发挥作用。 DIM-3,5-Cl2 (7-10 μM; 1, 2, 4, 6 h) 可时间依赖性地诱导人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中 CD71 蛋白及 CD71 mRNA 的表达,其中蛋白表达在 6 h 时被诱导,mRNA 表达在 4 h 时达到峰值。 DIM-3,5-Cl2 (15 μM; 24 h) 可在表达 NR4A1/NR4A2 的三阴性乳腺癌患者来源类器官 (TNBC PDxO) 模型 (BCM-HCI-3561、BCM-4175) 中诱导 CD71 蛋白表达。 DIM-3,5-Cl2 (10 μM) 可介导人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中 CD71 启动子活性的诱导,该作用依赖于 NR4A1 和 NR4A2 的表达,因为敲低其中任一受体均可消除该诱导作用。 DIM-3,5-Cl2 (10 μM; 4-24 h) 可时间依赖性地诱导人 MDA-MB-231 三阴性乳腺癌 (TNBC) 细胞中 Sp1、Sp4 和 CD71 的蛋白表达,且 CD71 的表达依赖于 Sp1 和 Sp4 的表达;因为敲低其中任一转录因子都会降低 CD71 的水平。 DIM-3,5-Cl2 (0.25-20 μM; 48 h) 可强效抑制 IHEEC 细胞 (IC50 = 7.34 μM) 和 IHESC 细胞 (IC50 = 5.78 μM) 的增殖,处理时间为 48 h。 DIM-3,5-Cl2 (6.5 μM; 24 h) 可显著抑制 IHEEC 和 IHESC 细胞的迁移。 DIM-3,5-Cl2 (6.5-13 μM; 24 h) 可以细胞类型特异性方式调控子宫内膜异位症相关通路蛋白的表达,下调增殖、纤维化及上皮间质转化 (EMT) 标志物,上调凋亡标志物,并降低 IHEEC 和 IHESC 细胞中的 NR4A1/NR4A2 水平。 DIM-3,5-Cl2 (13 μM; 12 h) 可降低纤维化及上皮间质转化 (EMT) 标志物 (COL1A1、N-钙黏蛋白、TWIST1) 的表达,并破坏 IHEEC 和 IHESC 细胞中的肌动蛋白丝结构。 DIM-3,5-Cl2 (5-10 μM; 24 h) 可降低人结肠癌细胞 SW480 中 NR4A1、Sp1 和 PD-L1 的蛋白表达水平。 DIM-3,5-Cl2 (2.5-7.5 μM; 24 h) 可下调人结肠癌细胞 RKO 中 NR4A1、Sp1 和 PD-L1 的蛋白表达水平。 DIM-3,5-Cl2 (2.5-7.5 μM; 24 h) 可降低 MC-38 小鼠结肠癌细胞中 NR4A1、Sp1 和 PD-L1 的蛋白表达水平。 DIM-3,5-Cl2 (7.5 μM; 3 h) 可降低 MC-38 小鼠结肠癌细胞中 NR4A1、Sp1 及 PolII 与 PD-L1 基因 GC 富集的近端启动子的结合作用。 DIM-3,5-Cl2 (10 μM; 3 h) 可降低 SW480 人结肠癌细胞中 NR4A1、Sp1 和 PolII 与 PD-L1 基因 GC 富集的近端启动子的结合作用。 DIM-3,5-Cl2 (7.5 μM; 3 h) 可降低人结肠癌细胞 RKO 中 NR4A1、Sp1 和 PolII 与 PD-L1 基因 GC 富集的近端启动子的结合能力。
Western Blot Analysis
| Cell Line: |
Human MDA-MB-231, MDA-MB-468, and mouse 4T1 triple negative breast cancer (TNBC) cells |
| Concentration: |
7, 10, 12, 15 μM (MDA-MB-231, MDA-MB-468); 10, 12, 15 μM (4T1) |
| Incubation Time: |
24 h |
| Result: |
Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 7, 10, 12 μM in MDA-MB-231 cells. Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 7, 10, 12, 15 μM in MDA-MB-468 cells. Induced cleaved PARP and cleaved caspase-3, and decreased BCL-2, full-length PARP, and full-length caspase-3 at 10, 12, 15 μM in 4T1 cells.\nDecreased GPX4 and SLC7A11 protein levels at 7, 10, 12 μM; induced CD71 protein levels at 7, 10 μM, and decreased CD71 at 12 μM in MDA-MB-231 cells. Decreased GPX4 and SLC7A11 protein levels at 7, 10, 12, 15 μM; induced CD71 protein levels at 7, 10 μM, and decreased CD71 at 12, 15 μM in MDA-MB-468 cells. Decreased GPX4 and SLC7A11 protein levels at 10, 12, 15 μM; induced CD71 protein levels at 10, 12, 15 μM in 4T1 cells. |
Western Blot Analysis
| Cell Line: |
Human MDA-MB-231 triple negative breast cancer (TNBC) cells |
| Concentration: |
10, 12 μM |
| Incubation Time: |
24 h |
| Result: |
Decreased expression of EGFR, β1-integrin, and c-Myc in MDA-MB-231 cells. |
Western Blot Analysis
| Cell Line: |
Human MDA-MB-231 triple negative breast cancer (TNBC) cells |
| Concentration: |
12 μM |
| Incubation Time: |
24 h |
| Result: |
Ferrostatin-1 significantly inhibited compound-mediated downregulation of CD71, GPX4, and SLC7A11 in MDA-MB-231 cells. |
Western Blot Analysis
| Cell Line: |
Human MDA-MB-231 triple negative breast cancer (TNBC) cells |
| Concentration: |
10 μM |
| Incubation Time: |
4, 6, 24 h |
| Result: |
Knockdown of Sp1 or Sp4 alone decreased CD71 protein expression in MDA-MB-231 cells. Induced Sp1, Sp4, and CD71 protein expression in MDA-MB-231 cells at 4, 6, and 24 h, with increasing induction observed over time. |
Cell Migration Assay
| Cell Line: |
Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC) |
| Concentration: |
6.5 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced migration of IHEEC and IHESC cells into the scratch wound area compared to vehicle controls, as measured by relative migration percentage. |
Western Blot Analysis
| Cell Line: |
Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC) |
| Concentration: |
6.5 μM; 13 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly decreased protein levels of EGFR, mTOR, phospho-mTOR, β1-integrin, CTGF, FN, COL1A1, TWIST1, Slug, Snail, Vimentin, N-cadherin, ZEB1, ZO-1, β-catenin, NR4A1, and NR4A2 in IHEEC cells. Significantly increased protein levels of cleaved poly(ADP-ribose) polymerase (C-PARP) and claudin-1 in IHEEC cells. Had no significant effect on ERβ levels in IHEEC cells. Significantly decreased protein levels of mTOR, phospho-mTOR, β1-integrin, ERβ, CTGF, COL1A1, TWIST1, Slug, Snail, N-cadherin, ZEB1, ZO-1, β-catenin, NR4A1, and NR4A2 in IHESC cells. Significantly increased protein levels of C-PARP and claudin-1 in IHESC cells. Had no significant effect on EGFR, FN, or α-SMA levels in IHESC cells. |
Immunofluorescence
| Cell Line: |
Immortalized human endometriotic epithelial cells (IHEEC), Immortalized human endometriotic stromal cells (IHESC) |
| Concentration: |
13 μM |
| Incubation Time: |
12 h |
| Result: |
Significantly reduced fluorescence intensity of COL1A1, N-cadherin, and TWIST1 compared to untreated controls in both IHEEC and IHESC cells. Caused a substantial decrease in filamentous actin structures in treated cells as shown by phalloidin staining. |
|
体内研究 (In Vivo) |
DIM-3,5-Cl2 (2.5 mg/kg;腹腔注射;每日;连续 34 天) 以 2.5 mg/kg 的剂量每日给药、连续 34 天,可显著降低子宫内膜异位症病灶的生长,抑制细胞增殖,促进细胞凋亡,下调病灶中的 Nr4a1 和 Nr4a2 表达,且在手术诱导的 Mus musculus (小家鼠) 子宫内膜异位症模型中不会引发明显毒性。 DIM-3,5-Cl2 (2.5-7.5 mg/kg/天;腹腔注射;每日给药;连续 21 天) 可显著抑制同源 C57BL/6 小鼠体内 MC-38 结肠肿瘤的生长,下调肿瘤 PD-L1 的表达,并逆转肿瘤浸润淋巴细胞 (TILs) 和脾脏 CD8+ T 细胞的耗竭状态。
| Animal Model: |
FVB/NJ (female, 6 weeks old, surgically induced endometriosis) |
| Dosage: |
2.5 mg/kg |
| Administration: |
i.p.; daily; 34 consecutive days |
| Result: |
Significantly reduced ectopic lesion volume compared to vehicle control. Significantly inhibited lesion growth as measured by luciferase imaging, while vehicle-treated mice showed continuous lesion growth. Significantly reduced Ki-67 expression in stromal cells of ectopic lesions; Ki-67 expression in epithelial cells was not significantly affected. Significantly increased TUNEL-positive (apoptotic) cells in ectopic lesions. Significantly reduced Nr4a1 expression in both epithelial and stromal cells of ectopic lesions; significantly reduced Nr4a2 expression in stromal cells, with no significant effect on epithelial Nr4a2 expression. Did not cause body weight loss, and liver panel analysis showed no evidence of liver damage compared to vehicle control. |
| Animal Model: |
C57BL/6 (female, 4-6 weeks old, subcutaneous implantation of MC-38 colon cancer cells) |
| Dosage: |
2.5 mg/kg/day; 7.5 mg/kg/day |
| Administration: |
i.p.; daily; 21 days |
| Result: |
Significantly decreased tumor volumes and tumor weights relative to controls. Showed no treatment-related toxicity, with treated mice showing a slight increase in body weight. Decreased expression of NR4A1 and PD-L1 in tumor lysates at 2.5 mg/kg/day dose. Significantly increased the percentage of CD8+ T-cells in tumor-infiltrating lymphocytes (TILs) at 2.5 mg/kg/day dose. Decreased the percentage of CD8+ T-cells expressing the T-cell exhaustion markers PD-1, 2B4, and TIM3, and decreased the percentage of CD8+ T-cells co-expressing PD-1 and TIM3 in TILs at 2.5 mg/kg/day dose. Decreased mRNA expression of NR4A1, TOX, TOX2, and NFAT, and increased mRNA expression of interferon γ, granzyme B, perforin, and T-Bet in CD8+ T-cells isolated from TILs at 2.5 mg/kg/day dose. Significantly increased cell percentages, decreased the percentage of cells expressing PD-1, 2B4, TIM3, and PD-1/TIM3, increased the percentage of Treg cells, increased the percentage of cells expressing T-Bet and TOX/TOX2, and decreased the percentage of cells expressing NFAT1 in splenic CD8+ T-cells at 2.5 mg/kg/day dose. |
|